Basal cell carcinoma - Basalis Cellula Carcinoma https://la.wikipedia.org/wiki/Epithelioma_basocellulare
Basalis Cellula Carcinoma (Basal cell carcinoma) est frequentissimum genus carcinomatis cutis. Saepe sine dolore, area dura cutis apparet. Lesio nitida potest habere vasa sanguinea superflua. Potest etiam se praebere ut ulcus levatum. Carcinoma basalis cellulae lente crescit et textus circum eam laedere potest, sed verisimile est metastasare aut mortem causare.

Factoribus periculis includuntur exposiō ad lucem ultraviolam, radium iustum, diuturna exposiō ad arsenicum et defectus immunitatis (e.g. transplantationis organorum). Expositio ad lucem UV in adolescentia maxime nocet.

Post diagnosis per biopsy, curatio optima est per remotionem chirurgicam. Et id excidi potest, si carcinoma parvus est; si carcinoma non parvus est, plerumque chirurgia Mohs commendatur.

Carcinoma basalis cellulae saltem 32 % omnium carcinomatum cutis in toto orbe computatur. Carcinomata cutis praeter melanoma circiter 80 % sunt carcinomata basali‑cellaria. In Civitatibus Foederatis, circiter 35 % virorum alborum et 25 % feminarum albarum, carcinomate basalis cellulae aliquando in vita afficiuntur.

○ Diagnosis et curatio
#Dermoscopy
#Skin biopsy
#Mohs surgery
Informationes plurimae ― Latine
References Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management 26029015 
NIH
Basal cell carcinoma (BCC) est frequentissimum genus carcinomatis cutis. Solis causa principalis est. Fere omnes casus BCC ericatrices hedgehog signum in analysi hypothetica ostendunt. Variae curationes praesto sunt et electae secundum periculum recidivae, momentum conservationis textus, praeferentias patientis, atque amplitudinem morbi.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
 Update in the Management of Basal Cell Carcinoma 32346750 
NIH
Basal cell carcinomas frequentissimae sunt cancri cutis in adultis supra 50 annorum. Eorum frequentia in toto orbe terrarum augescit, maxime ob expositionem solarum radiorum. Quaedam condiciones geneticae facile possunt efficere ut haec carcinomata in minore aetate appareant. Basal cell carcinomas in severitate variantur, a laesionibus superficialis et nodularibus facile tractabilibus ad casus graviores, quae discussionem medicam specialem requirunt. Prognosis pendet a probabilitate recidivae cancri vel eius facultate laedendi textum circumjacentem. Chirurgia est curatio praecipua in pluribus casibus, praesertim excisione et casibus humilitatis recurrentis. Modi incisi minus efficaciter laesiones superficiales tractare possunt.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
 European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023 37604067
Prima curatio BCC est chirurgica. In casu magni periculi vel BCC frequentissimae, praesertim in locis criticis, micrographica chirurgia moderata commendatur. Aegeribus cum humili periculo superficiali BCC tractationes topicae vel modi perniciosi considerari possunt. Photodynamica bene operatur contra nodulos superficiales et humiles BCCs. In casu BCC localiter provecti vel metastatici, inhibitores Hedgehog (vismodegib, sonidegib) commendantur. Si morbus progreditur vel intolerantia ad inhibitores Hedgehog est, immunoterapia cum anti‑PD1 anticorpo (cemiplimab) considerari potest. Radiotherapia optima optio est pro aegris qui chirurgiam subire non possunt, praesertim senioribus. Electrochemotherapy considerari potest si chirurgia vel radiotherapia non sunt optiones.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.